Advanced search
1 file | 1.17 MB

Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2-5 and on dialysis

Author
Organization
Abstract
In patients with chronic kidney disease (CKD), renal synthesis of active vitamin D [1,25-dihydroxyvitamin D (1,25(OH)(2)D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active vitamin D analogues in children with CKD-MBD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs has developed recommendations for the use of active vitamin D therapy in children with CKD and on dialysis. A second document in parallel with this one covers treatment recommendations for native vitamin D therapy. The WGs have performed an extensive literature review to include systematic reviews and randomized controlled trials in adults and children with CKD and prospective observational studies in children with CKD. The Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system was used to develop and grade the recommendations. In the absence of applicable study data, the opinion of experts from the ESPN CKD- MBD and Dialysis WGs is provided, but clearly GRADE-ed as such and must be carefully considered by the treating physician and adapted to individual patient needs as appropriate.
Keywords
CHRONIC-RENAL-FAILURE, INTERMITTENT CALCITRIOL THERAPY, RANDOMIZED, CONTROLLED-TRIALS, SECONDARY HYPERPARATHYROIDISM, PERITONEAL-DIALYSIS, PARATHYROID-HORMONE, BONE-DISEASE, MINERAL METABOLISM, GROWTH FAILURE, LINEAR GROWTH, chronic kidney disease (CKD), CKD-MBD, dialysis, pediatrics, vitamin D

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.17 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Shroff, Rukshana, Mandy Wan, Evi Nagler, Sevcan Bakkaloğlu, Mario Cozzolino, Justine Bacchetta, Alberto Edefonti, et al. 2017. “Clinical Practice Recommendations for Treatment with Active Vitamin D Analogues in Children with Chronic Kidney Disease Stages 2-5 and on Dialysis.” Nephrology Dialysis Transplantation 32 (7): 1114–1127.
APA
Shroff, R., Wan, M., Nagler, E., Bakkaloğlu, S., Cozzolino, M., Bacchetta, J., Edefonti, A., et al. (2017). Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2-5 and on dialysis. NEPHROLOGY DIALYSIS TRANSPLANTATION, 32(7), 1114–1127.
Vancouver
1.
Shroff R, Wan M, Nagler E, Bakkaloğlu S, Cozzolino M, Bacchetta J, et al. Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2-5 and on dialysis. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2017;32(7):1114–27.
MLA
Shroff, Rukshana, Mandy Wan, Evi Nagler, et al. “Clinical Practice Recommendations for Treatment with Active Vitamin D Analogues in Children with Chronic Kidney Disease Stages 2-5 and on Dialysis.” NEPHROLOGY DIALYSIS TRANSPLANTATION 32.7 (2017): 1114–1127. Print.
@article{8529340,
  abstract     = {In patients with chronic kidney disease (CKD), renal synthesis of active vitamin D [1,25-dihydroxyvitamin D (1,25(OH)(2)D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active vitamin D analogues in children with CKD-MBD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs has developed recommendations for the use of active vitamin D therapy in children with CKD and on dialysis. A second document in parallel with this one covers treatment recommendations for native vitamin D therapy. The WGs have performed an extensive literature review to include systematic reviews and randomized controlled trials in adults and children with CKD and prospective observational studies in children with CKD. The Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system was used to develop and grade the recommendations. In the absence of applicable study data, the opinion of experts from the ESPN CKD- MBD and Dialysis WGs is provided, but clearly GRADE-ed as such and must be carefully considered by the treating physician and adapted to individual patient needs as appropriate.},
  author       = {Shroff, Rukshana and Wan, Mandy and Nagler, Evi and Bakkalo\u{g}lu, Sevcan and Cozzolino, Mario and Bacchetta, Justine and Edefonti, Alberto and Stefanidis, Constantinos J and Vande Walle, Johan and Ariceta, Gema and Klaus, G{\"u}nter and Haffner, Dieter and Schmitt, Claus Peter},
  issn         = {0931-0509},
  journal      = {NEPHROLOGY DIALYSIS TRANSPLANTATION},
  language     = {eng},
  number       = {7},
  pages        = {1114--1127},
  title        = {Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2-5 and on dialysis},
  url          = {http://dx.doi.org/10.1093/ndt/gfx080},
  volume       = {32},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: